TX45 improved both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH‑HFrEF”) TX45 was well tolerated ...

BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, ...

Digitoxin reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and a reduced ejection fraction (HFrEF), according to ...

Tectonic Therapeutic ( ($TECX) ) has shared an announcement. On October 29, 2025, Tectonic Therapeutic announced positive topline data from its ...

Just 7% of HFrEF patients received quadruple therapy, and even in this group, the absolute risk of events at 1 year was high.

Panelists discuss how ARNIs like sacubitril-valsartan provide superior outcomes compared with ACE inhibitors in HFrEF (20% reduction in cardiovascular events, 16% mortality reduction), with broad FDA ...

NEW ORLEANS — A polypill containing a beta-blocker, a mineralocorticoid antagonist, and an SGLT2 inhibitor produced a substantial improvement in compliance to guideline-directed medical therapy for ...